We are live on ! Find out more
INSY

Insys Therapeutics, Inc.
INSY

Delisted

INSY was delisted on the 18th of June, 2019.

Back to rankings

110 hedge funds and large institutions have $136M invested in Insys Therapeutics, Inc. in 2018 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 28 increasing their positions, 25 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

64% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 11

44% more capital invested

Capital invested by funds: $94.2M → $136M (+$41.3M)

17% more call options, than puts

Call options by funds: $5.49M | Put options by funds: $4.68M

12% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 25

7% more funds holding

Funds holding: 103 → 110 (+7)

Holders
110
Holders Change
+7
Holders Change %
+6.8%
% of All Funds
2.51%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
18
Increased
28
Reduced
25
Closed
11
Calls
$5.49M
Puts
$4.68M
Net Calls
+$806K
Net Calls Change
+$3.44M

Top Buyers

Rank Fund Capital Flow
1
Norges Bank
Norges Bank
Norway
+$1.75M
2
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$1.2M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$955K
4
Millennium Management
Millennium Management
New York
+$949K
5
PAM
Panagora Asset Management
Massachusetts
+$803K

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$3.85M
2
Bank of Montreal
Bank of Montreal
Ontario, Canada
-$652K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$477K
4
Barclays
Barclays
United Kingdom
-$322K
5
VF
Virtu Financial
New York
-$253K
Name Holding Trade Value Shares
Change 		Change in
Stake
AF
101
Advisornet Financial
Minnesota
$1K – – –
Bessemer Group
102
Bessemer Group
New Jersey
$1K – – –
FHA
103
Flagship Harbor Advisors
Massachusetts
$1K – – –
AIM
104
Advantage Investment Management
Iowa
$1K +$838 +105 New
RE
105
RBC Europe
United Kingdom
$655 – – –
EMG
106
ETF Managers Group
New Jersey
– -$75 -868,770 Closed
Susquehanna International Group
107
Susquehanna International Group
Pennsylvania
– -$477K -59,757 Closed
VF
108
Virtu Financial
New York
– -$253K -34,988 Closed
TWA
109
TCI Wealth Advisors
Arizona
– -$56K -7,766 Closed
S
110
SignatureFD
Georgia
– -$7K -1,000 Closed
PIA
111
Piedmont Investment Advisors
North Carolina
– -$3K -467 Closed
WAM
112
Watermark Asset Management
California
– -$1K -200 Closed
PNC Financial Services Group
113
PNC Financial Services Group
Pennsylvania
– -$1K -100 Closed
FGAM
114
Financial Gravity Asset Management
Texas
– -$24 -3 -5%
HNB
115
Huntington National Bank
Ohio
– +$8 +1 New
1 2 3 4
5

INSY Hedge Fund Activity: Q3 2018 in Review

110 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Insys Therapeutics, Inc. (INSY) for Q3 2018, worth a combined $136M — up 44% from $94.2M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new INSY positions and 11 closed out — a net gain of 7 holders — while 28 added to existing stakes and 25 trimmed.

The largest buyer was Norges Bank, adding an estimated $1.75M. The largest seller was OrbiMed, cutting an estimated $3.85M.

  • 110 institutional investors held Insys Therapeutics, Inc. (INSY) as of Q3 2018, up from 103 in Q2 2018.
  • Funds reported $136M of Insys Therapeutics, Inc. stock for Q3 2018, up 44% quarter-over-quarter.
  • 18 funds opened new Insys Therapeutics, Inc. positions in Q3 2018 and 11 closed out, a net change of +7 holders.
  • The largest Insys Therapeutics, Inc. buyer in Q3 2018 was Norges Bank, an estimated $1.75M added.
  • The largest Insys Therapeutics, Inc. seller in Q3 2018 was OrbiMed, an estimated $3.85M sold.

Based on aggregated 13F filings for Q3 2018.